South Korea's biosimilar heavyweight Celltrion Inc. has obtained permission from the Canadian health ministry to sell anticancer biosimilar Vegzelma, the company said on Thursday.
Vegzelma is a biosimilar to Avastin (ingredient name Bevacizumab) used to cure metastatic direct bowel cancer, non-small cell lung cancer, metastatic breast cancer, and ovarian cancer.
The permission for Vegzelma covers the entire indications approved for Avastin, Celltrion explained.
“The approval of Vegzelma is an important milestone in Canada which continually implement biosimilar-friendly policies. We hope that Vegzelma, our third anticancer antibody biosimilar after Truxima and Herzuma, will shortly take root in the Canadian market," a Celltrion official said.
Write to Jae-Young Han at
jyhan@hankyung.com
